BridgeBio Pharma (NASDAQ:BBIO) CAO Maricel Apuli Sells 510 Shares

BridgeBio Pharma, Inc. (NASDAQ:BBIO) CAO Maricel Apuli sold 510 shares of BridgeBio Pharma stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $74.31, for a total value of $37,898.10. Following the transaction, the chief accounting officer directly owned 123,945 shares in the company, valued at approximately $9,210,352.95. The trade was a 0.41% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Maricel Apuli also recently made the following trade(s):

• On Monday, December 8th, Maricel Apuli sold 2,000 shares of BridgeBio Pharma stock. The stock was sold at an average price of $74.26, for a total transaction of $148,520.00.

BridgeBio Pharma Price Performance

Shares of NASDAQ:BBIO opened at $73.93 on Thursday. The company has a market capitalization of $14.25 billion, a P/E ratio of -17.69 and a beta of 1.13. BridgeBio Pharma, Inc. has a 1-year low of $28.33 and a 1-year high of $84.94. The firm’s 50 day simple moving average is $75.73 and its two-hundred day simple moving average is $63.79.

Hedge Funds Weigh In On BridgeBio Pharma

Several hedge funds have recently added to or reduced their stakes in BBIO. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in BridgeBio Pharma in the second quarter worth about $25,000. Aster Capital Management DIFC Ltd bought a new stake in shares of BridgeBio Pharma during the 3rd quarter worth approximately $31,000. Harvest Fund Management Co. Ltd purchased a new position in BridgeBio Pharma during the 3rd quarter valued at $34,000. Jones Financial Companies Lllp bought a new position in BridgeBio Pharma in the 1st quarter valued at $35,000. Finally, First Horizon Corp purchased a new stake in BridgeBio Pharma in the third quarter worth $36,000. 99.85% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on BBIO. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BridgeBio Pharma in a research note on Wednesday, January 21st. Sanford C. Bernstein assumed coverage on BridgeBio Pharma in a research note on Thursday, December 11th. They issued an “outperform” rating and a $94.00 price target for the company. Barclays began coverage on shares of BridgeBio Pharma in a research report on Wednesday, January 28th. They set an “overweight” rating on the stock. Truist Financial upped their target price on shares of BridgeBio Pharma from $80.00 to $86.00 and gave the stock a “buy” rating in a research report on Thursday, January 8th. Finally, Morgan Stanley started coverage on shares of BridgeBio Pharma in a report on Tuesday, January 6th. They issued an “overweight” rating and a $96.00 price target on the stock. Twenty-two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, BridgeBio Pharma presently has a consensus rating of “Moderate Buy” and an average price target of $82.05.

Trending Headlines about BridgeBio Pharma

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: Strong Phase 3 PROPEL 3 results in achondroplasia — a major clinical readout that improves the drug candidate’s regulatory and commercial outlook and is a clear fundamental upside driver for BBIO. PROPEL 3 Results
• Positive Sentiment: HC Wainwright boosted its price target to $100 and raised near‑term EPS estimates across Q2–Q4 and FY2026, reaffirming a Buy stance — analyst upgrades add conviction for longer‑term upside. HC Wainwright PT Raise
• Positive Sentiment: Broad analyst support remains strong (many Buy/Overweight ratings and median targets well above current levels), providing aftermarket analyst‑driven demand if clinical and financials meet expectations. Analyst Coverage Summary
• Neutral Sentiment: BridgeBio will report Q4 and full‑year 2025 results and host a Feb. 24 conference call — this scheduled event can create short‑term volatility depending on revenue, cash burn and program updates. Earnings Release
• Neutral Sentiment: Company granted inducement RSUs to 34 new hires (76,701 shares aggregate) — modest near‑term share‑based compensation and potential future dilution to monitor. Inducement Grants
• Neutral Sentiment: Oppenheimer added a small new position (7,845 shares) per 13F — modest institutional buying that is not yet material but shows some investor interest. Oppenheimer 13F
• Negative Sentiment: Clustered insider selling on Feb. 17 — Director Randal W. Scott sold 10,000 shares (~$754k) and other senior officers (including the CFO and CAO) filed sales the same day; concentrated insider disposals are weighing on near‑term sentiment. Insider Trades
• Negative Sentiment: Data providers and reporting highlight a history of executive selling — ongoing insider liquidity events can keep downward pressure on the stock until company insiders rebuild meaningful insider ownership. Insider/Sentiment Summary

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.